Merus N.V. (MRUS)
MRUS Stock Price Chart
Explore Merus N.V. interactive price chart. Choose custom timeframes to analyze MRUS price movements and trends.
MRUS Company Profile
Discover essential business fundamentals and corporate details for Merus N.V. (MRUS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 May 2016
Employees
260.00
Website
https://www.merus.nlCEO
Sven Ante Lundberg
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
MRUS Financial Timeline
Browse a chronological timeline of Merus N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$1.20, while revenue estimate is $8.70M.
Earnings released on 5 Aug 2025
EPS came in at -$2.23 falling short of the estimated -$1.17 by -90.60%, while revenue for the quarter reached $8.83M , missing expectations by -9.62%.
Earnings released on 7 May 2025
EPS came in at -$1.40 falling short of the estimated -$1.16 by -20.69%, while revenue for the quarter reached $26.49M , beating expectations by +255.59%.
Earnings released on 27 Feb 2025
EPS came in at -$0.41 surpassing the estimated -$0.89 by +53.93%, while revenue for the quarter reached $9.46M , missing expectations by -10.50%.
Earnings released on 31 Oct 2024
EPS came in at -$0.95 falling short of the estimated -$0.90 by -5.56%, while revenue for the quarter reached $13.15M , beating expectations by +50.78%.
Earnings released on 1 Aug 2024
EPS came in at -$0.81 falling short of the estimated -$0.76 by -6.58%, while revenue for the quarter reached $7.88M , missing expectations by -7.14%.
Earnings released on 8 May 2024
EPS came in at -$0.59 surpassing the estimated -$0.83 by +28.92%, while revenue for the quarter reached $8.47M , missing expectations by -13.08%.
Earnings released on 28 Feb 2024
EPS came in at -$1.09 falling short of the estimated -$0.71 by -53.52%, while revenue for the quarter reached $9.83M , missing expectations by -2.95%.
Earnings released on 2 Nov 2023
EPS came in at -$0.43 surpassing the estimated -$0.73 by +41.10%, while revenue for the quarter reached $11.64M , beating expectations by +6.48%.
Earnings released on 7 Aug 2023
EPS came in at -$0.66 surpassing the estimated -$0.86 by +23.26%, while revenue for the quarter reached $11.43M , beating expectations by +0.51%.
Earnings released on 4 May 2023
EPS came in at -$0.86 surpassing the estimated -$1.07 by +19.63%, while revenue for the quarter reached $14.68M , beating expectations by +29.98%.
Earnings released on 28 Feb 2023
EPS came in at -$1.81 falling short of the estimated -$0.84 by -115.48%, while revenue for the quarter reached $11.49M , beating expectations by +18.43%.
Earnings released on 3 Nov 2022
EPS came in at -$0.53 surpassing the estimated -$0.60 by +11.67%, while revenue for the quarter reached $6.43M , missing expectations by -41.55%.
Earnings released on 8 Aug 2022
EPS came in at -$0.13 surpassing the estimated -$0.65 by +80.00%, while revenue for the quarter reached $13.27M , beating expectations by +24.99%.
Earnings released on 9 May 2022
EPS came in at -$0.43 surpassing the estimated -$0.66 by +34.85%, while revenue for the quarter reached $12.89M , beating expectations by +37.64%.
Earnings released on 28 Feb 2022
EPS came in at -$0.34 surpassing the estimated -$0.58 by +41.38%, while revenue for the quarter reached $16.68M , beating expectations by +41.24%.
Earnings released on 2 Nov 2021
EPS came in at -$0.39 surpassing the estimated -$0.66 by +40.91%, while revenue for the quarter reached $15.87M , beating expectations by +19.56%.
Earnings released on 5 Aug 2021
EPS came in at -$0.71 falling short of the estimated -$0.60 by -18.33%, while revenue for the quarter reached $14.69M , beating expectations by +82.22%.
Earnings released on 6 May 2021
EPS came in at -$0.28 falling short of the estimated -$0.22 by -27.27%, while revenue for the quarter reached $9.82M , beating expectations by +27.88%.
Earnings released on 16 Mar 2021
EPS came in at -$0.77 falling short of the estimated -$0.61 by -26.23%, while revenue for the quarter reached $11.06M .
Earnings released on 5 Nov 2020
EPS came in at -$0.79 falling short of the estimated -$0.51 by -54.90%, while revenue for the quarter reached $10.06M , beating expectations by +34.18%.
MRUS Stock Performance
Access detailed MRUS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.